About
    XELJANZ in Action
    An alternative MoA targeting the JAK pathway1-3
    XELJANZ inhibits the effects of pro-inflammatory cytokines through intracellular targeting of the JAK pathway3
    •  
    • XELJANZ works inside the cell to inhibit inflammation by blocking JAK-dependent signalling pathways4​​​​​​​
    • This reduces the production of multiple pro-inflammatory cytokines4,5
    JAK, Janus kinase; MOA, mode of action
    References
    1.  
    2. XELJANZ (tofacitinib citrate) Summary of Product Characteristics.
    3. Tanaka Y, Yamaoka K. Mod Rheumatol 2012; 23:415–424.
    4. Fleischmann R. Curr Opin Rheumatol 2012; 24:335–341.
    5. O’Shea JJ et al. Ann Rev Med 2015; 66:311–328.
    6. McInnes IB, Liew FY. Nat Clin Pract Rheumatol 2005; 1:31–39
    7.  
    ​​​​​​​PP-XEL-GBR-3126. August 2021
    Request an eRep
    You can use the email below to contact a product representative and learn more about XELJANZ
    [email protected]
    XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

    © 2021 Pfizer Pte Ltd. All rights reserved.


    The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.